Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we desc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Tumori 2014-05, Vol.100 (3), p.e70-e73
Hauptverfasser:	Fiala, Ondrej, Pesek, Milos, Finek, Jindrich, Krakorova, Gabriela, Benesova, Lucie, Minarik, Marek
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma of Lung Adult Antineoplastic Agents - therapeutic use Bone Neoplasms - secondary ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics ErbB Receptors - metabolism Erlotinib Hydrochloride Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Mutation Pleural Effusion, Malignant - etiology Pleural Neoplasms - secondary Positron-Emission Tomography Protein Kinase Inhibitors - therapeutic use Quinazolines - therapeutic use Retreatment Thoracic Vertebrae Tomography, X-Ray Computed Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!